Renal & Urology NewsMetastasis-Directed Tx Shows ‘Robust’ Progression Benefit in Oligometastatic Prostate Cancer

The WOLVERINE meta-analysis — pooling individual patient data from 7 randomized trials — delivers the strongest evidence to date that metastasis-directed therapy cuts progression risk by 56% in oligometastatic prostate cancer. Overall survival benefit remains a trend and is not yet confirmed.

🔬 CLINICAL CONSIDERATIONS

• MDT plus standard-of-care reduced progression-free survival risk by 55-56% (HR 0.44-0.45) versus SOC alone at 3 years across both trial- and patient-level analyses
• Castration resistance-free survival improved 42% with MDT, a critical endpoint given the treatment complexity and cost burden of castration-resistant disease
• Patients with bone metastases showed significantly worse PFS than those with lymph node-only disease, warranting more cautious expectations when counseling this subgroup
• Adding ADT or second-generation ARPIs to MDT further improved PFS and rPFS (HR 0.38-0.45), suggesting combination sequencing outperforms MDT alone
• Grade 2+ adverse events were comparable between MDT plus SOC and SOC alone (17% vs 15%), offering meaningful reassurance for shared decision-making conversations

🎯 PRACTICE APPLICATIONS

• Apply MDT to appropriately selected oligometastatic patients as current evidence now supports routine use
• Stratify patient counseling by metastatic site; temper expectations for bone-dominant versus lymph node-dominant disease
• Sequence ADT or ARPI alongside MDT rather than MDT alone when clinically feasible
• Monitor ongoing trials refining patient selection and integration with modern systemic regimens before extrapolating broadly

More in Prostate Cancer